Product Details
Mar-Tadalafil
Tadalafil2.5 mg
Tablet
DIN/PIN/NPN
02452286
Manufacturer
Marcan Pharmaceuticals Inc.
Formulary Listing Date
2016-09-29
Unit Price
3.6471
Amount MOH Pays
3.6471
Coverage Status
Off-Formulary Interchangeable Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
G04BE08
Interchangeable Products
DIN/ PIN/ NPN | Brand name | Unit Price | Amount MOH pays |
---|---|---|---|
02440148 | Teva-Tadalafil | 3.8616 | 3.8616 |
02452081 | Ran-Tadalafil | 3.6471 | 3.6471 |
02409410 | PMS-Tadalafil | 3.6471 | 3.6471 |
02410621 | Mylan-Tadalafil | 3.6471 | 3.6471 |
02452286 | Mar-Tadalafil | 3.6471 | 3.6471 |
02451824 | Jamp-Tadalafil | 3.6471 | 3.6471 |
02296888 | Cialis | NA | NA |
02435896 | Auro-Tadalafil | 3.6470 | 3.6470 |
02422085 | Apo-Tadalafil | 3.6470 | 3.6470 |
02428628 | Act Tadalafil | 3.6471 | 3.6471 |
02512262 | PRZ-Tadalafil | 3.6470 | 3.6470 |
02536676 | Tadalafil | 3.8616 | 3.8616 |
LU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Cardiology Drugs | Tadalafil
For the treatment of severe Raynaud’s phenomenon (RP) and/or digital ulcers secondary to scleroderma (systemic sclerosis) or scleroderma-like disease:
Duration of initial approval: 6 months Renewals will be considered on a case-by-case basis for patients who demonstrate benefit from treatment (e.g., positive response in the duration, frequency and or severity of RP and/or improvement in the size or number of digital ulcers.) |
Pulmonary Arterial Hypertension | Sildenafil
Tadalafil
Drugs for Pulmonary Arterial Hypertension (PAH) under EAP
All requests (initial, renewal, monotherapy, combination therapy) for a PAH drug must come from one of the following recognized PAH referral centres:
Requests from other physicians/centres must include a recent (less than or equal to 3 months old) consult note/recommendation from a recognized PAH referral centre that supports the request; Out-of-province referral centre consults (e.g., from Winnipeg for patients in Northern Ontario) will also be considered on a case-by-case basis Initial Criteria: For the treatment of patients with pulmonary arterial hypertension (PAH) [WHO Group 1 Pulmonary hypertension] who meet all the following criteria:
1Note: Left ventricular end-diastolic pressure ≤ 15 mmHg is also acceptable. For all funded PAH Drugs, case-by-case consideration may be provided for the following:
Exclusion Criteria: Combinations of drugs targeting similar pathways will not be funded (i.e., combination regimen may only include one agent from each drug class -- phosphodiesterase type 5 [PDE-5] inhibitors, endothelin receptor antagonists (ERA), and/or prostanoids) Renewal criteria for funded PAH Drugs: Renewals will be provided for patients who remain under the care of a physician from a recognized PAH Centre (see list above) and who continue to benefit from therapy. Approval Durations: EAP Drug Request Form: |